Dual-Responsive Epigenetic Inhibitor Nanoprodrug Combined with Oncolytic Virus Synergistically Boost Cancer Immunotherapy by Igniting Gasdermin E-Mediated Pyroptosis

Yuanyuan Wang, Jingting Wang, Shuo Wang, Qi‐Chao Yang, An Song, Mengjie Zhang, Wenda Wang, Yuan‐Tong Liu, Junjie Zhang, Wei‐Ming Wang, Zhigang Xu, Zhi‐Jun Sun, Zhi-Jun SunACS 2024 · DOI

Abstract

Cancer immunotherapy has emerged as a promising approach for the treatment of various cancers. However, the immunosuppressive tumor microenvironment (TME) limits the efficacy of current immunotherapies. In this study, we designed a dual-responsive DNA methyltransferase inhibitor nanoprodrug ACNPs for combination therapy with oncolytic herpes simplex virus (oHSV). We found that the epigenetic inhibitor 5-Azacytidine (5-Aza) upregulated gasdermin E (GSDME) expression at the gene level, whereas the oHSV decreased the ubiquitination and degradation of GSDME to elevate its levels. Based on these observations, we further discovered that ACNPs and oHSV synergistically enhanced GSDME-mediated pyroptosis. Additionally, the combination therapy of ACNPs and oHSV effectively inhibited tumor growth, remodeled the immunosuppressive TME, and improved the efficacy of immune checkpoint blockade (ICB) therapy. These results demonstrate the potential to overcome immunosuppression through synergistic combinations, offering a promising approach for cancer immunotherapy.
BibTeX
@inproceedings{wang2024dual,
  author = {Yuanyuan Wang and Jingting Wang and Shuo Wang and Qi‐Chao Yang and An Song and Mengjie Zhang and Wenda Wang and Yuan‐Tong Liu and Junjie Zhang and Wei‐Ming Wang and Zhigang Xu and Zhi‐Jun Sun and Zhigang Xu and Zhi-Jun Sun},
  title = {{Dual-Responsive Epigenetic Inhibitor Nanoprodrug Combined with Oncolytic Virus Synergistically Boost Cancer Immunotherapy by Igniting Gasdermin E-Mediated Pyroptosis}},
  booktitle = {ACS},
  year = {2024},
  doi = {10.1021/acsnano.4c03034},
}

Loading related content...

Figure